lifestyle.mmminimal.com

Author: Humacyte, Inc

Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

March 19, 2026
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

March 19, 2026
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

March 17, 2026
Humacyte To Participate in Upcoming Investor Conferences

March 2, 2026
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

February 18, 2026
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

February 12, 2026